Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Roche's Kadcyla, a Breast Cancer Treatment, Is First ADC Approved in China

publication date: Jan 24, 2020

Roche announced Kadcyla has been approved in China as an adjuvant treatment for HER-2 positive breast cancer, the first antibody drug conjugate approved in China. In clinical trials, Kadcyla outperformed Herceptin, another Roche product that is now facing biosimilar competition. Kadcyla combines the HER2-targeting properties of Herceptin and the cytotoxic chemotherapy agent DM1. In a clinical trial, Kadcyla reduced the risk of invasive breast cancer recurrence or death from any cause by 50% compared to Herceptin. At three years, 88% of Kadcyla patients did not have a recurrence of their disease against 77% of Herceptin patients. More details....

Stock Symbol: (SWX: ROG)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022